Study of LY3962681 Given by Spinal Injection to Healthy Adults and to Adults With Parkinsons Disease to Evaluate Safety and Effects

What this Trial Is About

Researchers are evaluating the safety, tolerability, and behavior in the body pharmacokineticspharmacodynamics of a drug called LY3962681 in both healthy volunteers and patients with Parkinsons disease. This study is divided into two parts the Single Ascending Dose SAD study involving healthy participants and the Multiple Ascending Dose MAD study involving Parkinsons patients. The study aims to understand how the drug works and how safe it is when given in different doses. In the SAD part, healthy volunteers will receive one dose of LY3962681 or a placebo injected into the spinal fluid. In the MAD part, Parkinsons patients will receive two doses of the drug or placebo, also injected into the spinal fluid, spaced 12 to 24 weeks apart. The SAD treatment lasts one day, while the MAD treatment includes two dosing days separated by a few months. Participants will be monitored for up to 52 weeks after their final dose. During this time, researchers will watch for any serious or new side effects, track how the drug moves and acts in the body, and measure changes in specific Parkinsons disease markers in spinal fluid. The study involves medical evaluations, cognitive tests, and safety monitoring throughout the follow-up period to ensure participant well-being.

A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease